Quote this publication Share Print

KEVZARA (sarilumab), interleukin 6 receptor inhibitor

RHEUMATOLOGY - New medicinal product
Opinions on drugs - Posted on Apr 12 2018

Reason for request

Inclusion

Substantial actual benefit but no clinical benefit demonstrated in the treatment of rheumatoid arthritis after failure of one or more disease-modifying treatments

 

  • KEVZARA, administered subcutaneously, has Marketing Authorisation in the treatment of rheumatoid arthritis (RA) after failure of one or more disease-modifying treatments. 
  • It is a second-line treatment after failure of conventional disease-modifying treatments such as methotrexate (MTX) or a third-line treatment (failure of a biological medicinal product) or beyond (failure of multiple conventional disease-modifying and/or biological treatments).
  • Its superiority has been demonstrated in monotherapy compared with adalimumab in second-line (inadequate response or intolerance to MTX) treatment.

 

»  KEVZARA has not been compared to available third-line alternatives, in particular the other anti-IL6 (tocilizumab), abatacept or rituximab.

 

 


Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Contact Us

Évaluation des médicaments